Innate Pharma SA ( (FR:IPH) ) just unveiled an update.
On April 16, 2025, Innate Pharma announced its proposal to transition its corporate governance structure from an executive board/supervisory board to a CEO/board of directors model, to be voted on at the Annual General Meeting on May 22, 2025. This change aims to align the company’s governance with international standards and enhance long-term value creation. If approved, Irina Staatz-Granzer will become Chairwoman of the board, and Jonathan Dickinson will be appointed CEO. The proposal also includes appointing two new board members, reflecting the company’s commitment to strong governance and investor feedback.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company leverages its proprietary ANKET® platform to create multi-specific NK Cell Engagers, Antibody Drug Conjugates, and monoclonal antibodies. Innate Pharma collaborates with major biopharmaceutical companies like Sanofi and AstraZeneca to advance its innovative treatments.
YTD Price Performance: -50.0%
Average Trading Volume: 1,075
Technical Sentiment Signal: Strong Buy
Current Market Cap: $165M
Find detailed analytics on IPH stock on TipRanks’ Stock Analysis page.